Show simple item record

dc.contributor.authorVan Cutsem, E.
dc.contributor.authorDanielewicz, I.
dc.contributor.authorSaunders, Mark P
dc.contributor.authorPfeiffer, P.
dc.contributor.authorArgilés, G.
dc.contributor.authorBorg, C.
dc.contributor.authorGlynne-Jones, R.
dc.contributor.authorPunt, C. J. A.
dc.contributor.authorVan de Wouw, A. J.
dc.contributor.authorFedyanin, M.
dc.contributor.authorStroyakovskiy, D.
dc.contributor.authorKroening, H.
dc.contributor.authorGarcia-Alfonso, P.
dc.contributor.authorWasan, H.
dc.contributor.authorFalcone, A.
dc.contributor.authorFougeray, R.
dc.contributor.authorEgorov, A.
dc.contributor.authorAmellal, N.
dc.contributor.authorMoiseyenko, V.
dc.date.accessioned2022-05-26T08:35:10Z
dc.date.available2022-05-26T08:35:10Z
dc.date.issued2022en
dc.identifier.citationVan Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Vol. 126, British Journal of Cancer. Springer Science and Business Media LLC; 2022. p. 1548–54.en
dc.identifier.pmid35440667en
dc.identifier.doi10.1038/s41416-022-01737-2en
dc.identifier.urihttp://hdl.handle.net/10541/625264
dc.description.abstractBackground: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall survival (OS) results. Methods: TASCO1 was an open-label, non-comparative phase II trial. Patients (n = 153) were randomised 1:1 to TT-B (trifluridine/tipiracil 35 mg/m2 orally twice daily on days 1-5 and 8-12, and bevacizumab intravenously 5 mg/kg on days 1 and 15 of each 28-day cycle) or capecitabine plus bevacizumab (C-B; capecitabine, 1250 mg/m2 orally twice daily on days 1-14 and bevacizumab 7.5 mg/kg intravenously on day 1 of each 21-day cycle). Final OS was analysed when all patients had either died or withdrawn from the study. Adjusted multivariate regression was used to investigate the effects of pre-specified variables on OS. Results: At 1 September 2020, median OS was 22.3 months (95% CI: 18.0-23.7) with TT-B and 17.7 months (95% CI: 12.6-19.8) with C-B (adjusted HR 0.78; 95% CI: 0.55-1.10). No variables negatively affected OS with TT-B. Safety results were consistent with prior findings. Conclusions: TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-022-01737-2en
dc.titleFirst-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 studyen
dc.typeArticleen
dc.contributor.departmentUniversity Hospitals Leuven and KU Leuven, Leuven, Belgiumen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]
refterms.dateFOA2022-06-29T09:07:05Z


Files in this item

Thumbnail
Name:
35440667.pdf
Size:
685.7Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record